Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,101.60 -14.57 (-0.28%) Dow
38,199.78 -186.31 (-0.49%) Nasdaq
15,934.34 -48.74 (-0.30%) Bitcoin USD
62,955.66 -677.18 (-1.06%) CMC Crypto 200
1,299.10 -39.97 (-2.99%)
Moderna, Inc. (MRNA)
| Previous close | 111.62 |
| Open | 110.50 |
| Bid | 111.59 x 600 |
| Ask | 112.02 x 200 |
| Day's range | 109.55 - 111.95 |
| 52-week range | 62.55 - 142.79 |
| Volume | |
| Avg. volume | 3,771,398 |
| Market cap | 42.84B |
| Beta (5Y monthly) | 1.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation Package
Key Insights Moderna to hold its Annual General Meeting on 6th of May CEO Stephane Bancel's total compensation includes...
- Benzinga
mRNA Is Promising A Breakthrough In Fighting Cancer
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it allowed pharmaceutical companies like Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) to develop their groundbreaking vaccines in record time. By the looks of it, this was only the beginning of the healthcare revolution that mRNA triggered. Mainz Biomed N.V. (NASDAQ: MYNZ) to revolutionize c
- Zacks
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
